Want to join the conversation?
Pharma company $MRK said a Phase 2 study of its investigational beta-lactamase inhibitor, relebactam, in combination with imipenem/cilastatin in patients with urinary tract infections met its primary endpoint. Two Phase 3 clinical studies of relebactam in combination with imipenem/cilastatin are currently ongoing and recruiting patients.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?